Ethical considerations of neuro-oncology trial design in the era of precision medicine

The field of oncology is currently undergoing a paradigm shift. Advances in the understanding of tumor biology and in tumor sequencing technology have contributed to the shift towards precision medicine, the therapeutic framework of targeting the individual oncogenic changes each tumor harbors. The success of precision medicine therapies, such as targeted kinase inhibitors and immunotherapies, in other cancers have motivated studies in brain cancers. The high specificity and cost of these therapies also encourage a shift in clinical trial design away from randomized control trials towards smaller, more exclusive early phase clinical trials. While these new trials advance the clinical application of increasingly precise and individualized therapies, their design brings ethical challenges . We review the pertinent ethical considerations for clinical trials of precision medicine in neuro-oncology and discuss methods to protect patients in this new era of trial design.

• Publication year

  2017

• Venue

  Journal of Neuro-Oncology

• Publication date

  2017-05-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11060-017-2502-0PMID 28555425PMCID 5543186
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

  2016cited by this paper
• Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.

  2016cited by this paper
• Precision medicine ethics: selected issues and developments in next-generation sequencing, clinical oncology, and ethics

  2016cited by this paper
• Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.

  2016cited by this paper
• A Survey of U.S Adults’ Opinions about Conduct of a Nationwide Precision Medicine Initiative® Cohort Study of Genes and Environment

  2016cited by this paper
• Global trends on fears and concerns of genetic discrimination: a systematic literature review

  2016cited by this paper
• Patient and interest organizations’ views on personalized medicine: a qualitative study

  2016cited by this paper
• Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered

  2016cited by this paper
• Drifting Away from Informed Consent in the Era of Personalized Medicine.

  2015cited by this paper
• Ask Not What Personalized Medicine Can Do for You - Ask What You Can Do for Personalized Medicine

  2015cited by this paper
• Incidental Findings with Genomic Testing: Implications for Genetic Counseling Practice

  2015cited by this paper
• Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine.

  2014cited by this paper
• Personalized Medicine, Availability, and Group Disparity: An Inquiry into How Physicians Perceive and Rate the Elements and Barriers of Personalized Medicine

  2014cited by this paper
• Just caring: assessing the ethical and economic costs of personalized medicine.

  2014cited by this paper
• Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility

  2014cited by this paper
• Traditional Roles in a Non-Traditional Setting: Genetic Counseling in Precision Oncology

  2014cited by this paper
• Ethics, Evidence and Economics in the Pursuit of “Personalized Medicine”

  2014cited by this paper
• Genetic Information, Non-Discrimination, and Privacy Protections in Genetic Counseling Practice

  2014cited by this paper
• Educating physicians in the era of genomic medicine

  2014cited by this paper
• "N of 1" case reports in the era of whole-genome sequencing.

  2013cited by this paper
• Translating genomics in cancer care.

  2013cited by this paper
• Revealing the incidentalome when targeting the tumor genome.

  2013cited by this paper
• A Patient-Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of Haystacks and Needles

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

  2012cited by this paper
• Feedback of individual genetic results to research participants: in favor of a qualified disclosure policy

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Views of Discrimination among Individuals Confronting Genetic Disease

  2010cited by this paper
• Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

  2009cited by this paper
• Do patients understand?

  2008cited by this paper
• Targeted drug therapy for meningiomas.

  2007cited by this paper
• Targeted cancer therapy

  2004cited by this paper
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper

• Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects

  2026cites this paper
• Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma

  2026cites this paper
• The ‘power of 1’: The ethics and epistemology of ‘N-of-1 trials’ in oncology

  2025cites this paper
• A Theoretical Framework for Ligand-Functionalised Magnetic Lipid Nanoparticles in Glioblastoma Therapy

  2025cites this paper
• Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier

  2024cites this paper
• Navigating ethical challenges of integrating genomic medicine into clinical practice: Maximising beneficence in precision oncology

  2024cites this paper
• Freiburg Neuropathology Case Conference

  2024cites this paper
• Is it Time to Introduce the “Precision Tutorial System” for Undergraduate?

  2022cites this paper
• Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis

  2021influential citation
• Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country

  2021cites this paper
• Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?

  2019cites this paper
• Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology

  2018cites this paper
• Earliest radiological progression in glioblastoma by multidisciplinary consensus review

  2018cites this paper
• Patient and interest organizations’ views on personalized medicine: a qualitative study

  2016cites this paper
• Recurrent glioblastoma in the era of molecular diagnostics: practice variation and practical implications

  year unknowncites this paper